Premium
Immunogenicity and antitumor activity of a liposomal MUC1 peptide‐based vaccine
Author(s) -
Samuel John,
Budzynski Wladyslaw A.,
Reddish Mark A.,
Ding Lei,
Zimmermann Gabrielle L.,
Krantz Mark J.,
Koganty R. Rao,
Longenecker B. Michael
Publication year - 1998
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/(sici)1097-0215(19980119)75:2<295::aid-ijc20>3.0.co;2-b
Subject(s) - immunogenicity , muc1 , peptide , medicine , peptide vaccine , liposome , virology , immunology , biology , immune system , antigen , epitope , biochemistry
A human MUC 1‐transfected mouse mammary adenocarcinoma cell line (GZHI) was used to develop both subcutaneous and intravenous tumor models. A vaccine formulation comprised of a 24 mer (human MUC1) synthetic peptide encapsulated with monophosphoryl lipid A adjuvant (MPLA) in multilamellar liposomes was tested for immunogenicity and anti‐tumor activity. A low dose of the human MUC1 peptide (5 μg) administered in liposomes provided excellent protection of mice in both tumor challenge models. The protective antitumor activity mediated by the liposome formulation correlated with anti‐MUC1‐specific T‐cell proliferation, gamma‐interferon (IFN‐γ) production and IgG 2a anti‐MUC1 antibodies, suggesting a type 1 (T 1 ) T‐cell response. In contrast, lack of protection in mice immunized with negative control vaccines correlated with IgG 1 anti‐MUC1 antibody formation, low or no anti‐MUC1 IgG 2a and low antigen‐specific T‐cell proliferation, consistent with a type 2 (T 2 ) T‐cell response to the tumor. Int. J. Cancer 75:295–302, 1998. © 1998 Wiley‐Liss, Inc.